Twist Bioscience Corp
TWST34.055USD
-0.984-2.81%
Market hours （ET）Quotes delayed by 15 min
2.04BMarket Cap
LossP/E TTM
More Details of Twist Bioscience Corp Company
Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. It has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The Company's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. It has minority ownership in Atlas Data Storage, Inc.
Company Info
Ticker SymbolTWST
Company nameTwist Bioscience Corp
IPO dateOct 31, 2018
Founded at2013
CEODr. Emily M. Leproust, Ph.D.
Number of employees923
Security typeOrdinary Share
Fiscal year-endOct 31
Address681 Gateway Blvd.
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94080
Phone18007190671
Websitehttps://www.twistbioscience.com/
Ticker SymbolTWST
IPO dateOct 31, 2018
Founded at2013
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
343.35K
-0.63%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
116.05K
-17.54%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
92.71K
+5.07%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
50.48K
-0.51%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
47.51K
-1.76%
Mr. Nelson C. Chan
Mr. Nelson C. Chan
Independent Director
Independent Director
22.25K
+25.16%
Dr. Melissa A. Starovasnik, Ph.D.
Dr. Melissa A. Starovasnik, Ph.D.
Independent Director
Independent Director
15.81K
+39.44%
Mr. Jan Johannessen
Mr. Jan Johannessen
Independent Director
Independent Director
12.60K
+55.04%
Mr. Adam Laponis
Mr. Adam Laponis
Chief Financial Officer
Chief Financial Officer
10.70K
-8.04%
Mr. Robert Werner
Mr. Robert Werner
Chief Accounting Officer, Vice President
Chief Accounting Officer, Vice President
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
343.35K
-0.63%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
116.05K
-17.54%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
92.71K
+5.07%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
50.48K
-0.51%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
47.51K
-1.76%
Mr. Nelson C. Chan
Mr. Nelson C. Chan
Independent Director
Independent Director
22.25K
+25.16%
Revenue Breakdown
Currency: USDUpdated: Sun, Apr 6
Currency: USDUpdated: Sun, Apr 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
NGS tools
48.64M
54.83%
Synthetic genes
26.48M
29.85%
Antibody discovery
5.70M
6.42%
Oligo pools
5.09M
5.74%
DNA and Biopharma libraries
2.79M
3.15%
DNA libraries
2.79M
3.15%
By RegionUSD
Name
Revenue
Proportion
Americas
53.71M
60.54%
EMEA
28.30M
31.91%
APAC
6.70M
7.55%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
NGS tools
48.64M
54.83%
Synthetic genes
26.48M
29.85%
Antibody discovery
5.70M
6.42%
Oligo pools
5.09M
5.74%
DNA and Biopharma libraries
2.79M
3.15%
DNA libraries
2.79M
3.15%
Shareholding Stats
Updated: Tue, May 20
Updated: Tue, May 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
10.42%
The Vanguard Group, Inc.
9.77%
Artisan Partners Limited Partnership
9.77%
BlackRock Institutional Trust Company, N.A.
7.73%
William Blair Investment Management, LLC
6.35%
Other
55.96%
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
10.42%
The Vanguard Group, Inc.
9.77%
Artisan Partners Limited Partnership
9.77%
BlackRock Institutional Trust Company, N.A.
7.73%
William Blair Investment Management, LLC
6.35%
Other
55.96%
Shareholder Types
Shareholders
Proportion
Investment Advisor
51.92%
Investment Advisor/Hedge Fund
49.22%
Hedge Fund
8.42%
Research Firm
3.10%
Individual Investor
1.98%
Pension Fund
1.42%
Bank and Trust
0.41%
Sovereign Wealth Fund
0.27%
Family Office
0.24%
Institutional Shareholding
Updated: Tue, Mar 4
Updated: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
565
67.44M
112.56%
-7.04M
2024Q4
578
67.47M
113.11%
-8.03M
2024Q3
588
67.80M
115.74%
-8.48M
2024Q2
579
66.59M
114.39%
-10.53M
2024Q1
565
68.18M
117.94%
-8.61M
2023Q4
559
67.81M
117.39%
-11.70M
2023Q3
560
68.09M
118.66%
-11.36M
2023Q2
577
69.42M
121.49%
-5.07M
2023Q1
593
64.77M
113.93%
-4.20M
2022Q4
610
60.52M
106.86%
-2.15M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
ARK Investment Management LLC
6.38M
10.7%
+786.30K
+14.05%
Feb 28, 2025
The Vanguard Group, Inc.
5.79M
9.71%
+189.79K
+3.39%
Dec 31, 2024
Artisan Partners Limited Partnership
5.89M
9.88%
-125.19K
-2.08%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
4.62M
7.75%
+119.93K
+2.66%
Dec 31, 2024
William Blair Investment Management, LLC
2.95M
4.95%
-527.57K
-15.17%
Dec 31, 2024
Invesco Advisers, Inc.
3.53M
5.92%
+25.56K
+0.73%
Dec 31, 2024
State Street Global Advisors (US)
2.54M
4.26%
-623.36K
-19.68%
Dec 31, 2024
Nikko Asset Management Co., Ltd.
2.61M
4.38%
-248.70K
-8.69%
Dec 31, 2024
Thrivent Asset Management, LLC
1.51M
2.52%
+532.04K
+54.64%
Dec 31, 2024
View more
Related ETFs
Updated: Fri, Jun 6
Updated: Fri, Jun 6
Name
Proportion
ARK Genomic Revolution ETF
6.34%
iShares Genomics Immunology and Healthcare ETF
2.62%
ARK Innovation ETF
2.1%
Global X Genomics & Biotechnology ETF
2.01%
WisdomTree BioRevolution Fund
1.82%
Franklin Genomic Advancements ETF
1.65%
ROBO Global Healthcare Technology & Innovation ETF
1.15%
BNY Mellon Innovators ETF
1.13%
Putnam Sustainable Future ETF
0.92%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.85%
View more
ARK Genomic Revolution ETF
Proportion6.34%
iShares Genomics Immunology and Healthcare ETF
Proportion2.62%
ARK Innovation ETF
Proportion2.1%
Global X Genomics & Biotechnology ETF
Proportion2.01%
WisdomTree BioRevolution Fund
Proportion1.82%
Franklin Genomic Advancements ETF
Proportion1.65%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.15%
BNY Mellon Innovators ETF
Proportion1.13%
Putnam Sustainable Future ETF
Proportion0.92%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion0.85%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
